Ontology highlight
ABSTRACT:
SUBMITTER: Verstovsek S
PROVIDER: S-EPMC4414320 | biostudies-literature | 2014 Mar
REPOSITORIES: biostudies-literature
Verstovsek Srdan S Tam Constantine S CS Wadleigh Martha M Sokol Lubomir L Smith Catherine C CC Bui Lynne A LA Song Chunyan C Clary Douglas O DO Olszynski Patrycja P Cortes Jorge J Kantarjian Hagop H Shah Neil P NP
Leukemia research 20131211 3
This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300 mg orally on days 1-21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppres ...[more]